scFv(CD19)-OX40-CD3zeta CAR-T Lentivirus

Chimeric antigen receptor (CAR) T cells have become a paradigm shift in cancer immunotherapy, marking a milestone in the history of cancer treatment. In 2017, the FDA approved two CAR-T cell therapies targeting CD-19, both demonstrating significant efficacy in B-cell lymphomas. Currently, a variety of CAR-T designs are under investigation for immunotherapy of hematological malignancies and even solid tumors. Lentiviral vectors (LVs) are widely used to generate CAR-T cells in vitro due to their ability to stably integrate large DNA fragments into both dividing and non-dividing cells.

Both viral and non-viral vectors can be used for CAR-T cell production. Among viral vectors, lentiviral vectors (LVs) are considered the most promising gene therapy vectors due to their efficient integration into the target cell genome and stable gene expression. Compared to other viral vectors, lentiviral vector integration patterns have a lower risk of oncogenicity and random gene integration. Therefore, lentiviral vector production of CAR-T cells is safer, more effective, and more flexible. More importantly, lentiviral vectors offer relatively low production costs compared to other viral vectors. In addition, lentiviral vectors can transduce both differentiated and undifferentiated cells. Therefore, lentiviral vectors can transduce a wider range of cells, including those that are difficult to transduce, such as blood progenitor cells, neural cells, lymphocytes, and macrophages.